Drug comparisons
Linagliptin vs Glyburide
Compare Linagliptin (DPP-4) vs Glyburide (sulfonylurea) for type 2 diabetes: efficacy, hypoglycemia risk, weight effects, and renal safety.
No comparison dimensions are available for this page.
Clinical context
This comparison arises when selecting between a DPP-4 inhibitor and a sulfonylurea for type 2 diabetes, particularly in patients at elevated hypoglycemia or renal risk.
Bottom line
Linagliptin typically offers a more favorable safety profile than Glyburide for most type 2 diabetes patients.
All medication comparisons